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A B S T R A C T   
Background: Questionnaires are the current hallmark for quantifying social functioning in human clinical research. In this study, we compared self- and proxy-rated 
(caregiver and researcher) assessments of social functioning in Schizophrenia (SZ) and Alzheimer’s disease (AD) patients and evaluated if the discrepancy between 
the two assessments is mediated by disease-related factors such as symptom severity. 
Methods: We selected five items from the WHO Disability Assessment Schedule 2.0 (WHODAS) to assess social functioning in 53 AD and 61 SZ patients. Caregiver- and 
researcher-rated assessments of social functioning were used to calculate the discrepancies between self-rated and proxy-rated assessments. Furthermore, we used the 
number of communication events via smartphones to compare the questionnaire outcomes with an objective measure of social behaviour. 
Results: WHODAS results revealed that both AD (p < 0.001) and SZ (p < 0.004) patients significantly overestimate their social functioning relative to the assessment 
of their caregivers and/or researchers. This overestimation is mediated by the severity of cognitive impairments (MMSE; p = 0.019) in AD, and negative symptoms 
(PANSS; p = 0.028) in SZ. Subsequently, we showed that the proxy scores correlated more strongly with the smartphone communication events of the patient when 
compared to the patient-rated questionnaire scores (self; p = 0.076, caregiver; p < 0.001, researcher-rated; p = 0.046). 
Conclusion: Here we show that the observed overestimation of WHODAS social functioning scores in AD and SZ patients is partly driven by disease-related biases such 
as cognitive impairments and negative symptoms, respectively. Therefore, we postulate the development and implementation of objective measures of social 
functioning that may be less susceptible to such biases.   
1. Introduction 
To date, the quantification of human behavioural constructs in 
biomedical studies predominantly rely on subjective research methods 
such as in-person interviews, questionnaires and self- or proxy-rated 
measures. The use of these methods over the past century evidently 
led to numerous important insights in disciplines such as psychiatry, 
sociology, economy, and even other disciplines in medicine. In psychi-
atry, for example, these methods are recently utilized to study the bio-
logical underpinnings of behavioural symptoms, such as social 
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withdrawal in neuropsychiatric patients (van der Wee et al., 2019). 
Despite their wide use in research, these behavioural assessment 
methods have limitations that impede their objectivity. Most notably, 
these methods may depend on the participant’s (or the participant’s 
proxy) account of behaviour, and are consistently obtained post-hoc, i.e. 
questionnaire measures of behaviour are virtually never real-time. 
Observational assessments are real-time but they occur nearly always 
in a non-natural (e.g., clinical) setting and are relatively costly and time 
consuming. 
Due to these limitations, current behavioural assessment methods 
are susceptible to various method and response biases (Podsakoff et al., 
2003). These biases or so-called measurement errors preclude the ac-
curate collection of behavioural phenotypic data from humans and 
thereby limit our ability to understand variations in human behaviour. 
For example, these measurement errors interfere with the dependencies 
between behavioural measures and biological parameters, such as ge-
notypes, brain activity patterns or structural brain data used to study the 
biological underpinnings of the observed behaviour. In addition, the 
search for effective treatments for social functioning (e.g. clinical trials 
for negative symptoms in schizophrenia) has always encountered the 
difficult question to determine outcomes as defined by patients or by 
proxies such as relatives (Bugarski-Kirola et al., 2017; Fraguas et al., 
2019; Galderisi et al., 2018). Subsequently, these distorted or 
miss-conceptualized dependencies between readouts might lead to 
wrong conclusions and explanations of behaviour and clinical trials and 
thus limits our understanding of the biological underpinnings of 
behaviour and interpretation of randomized clinical trials (RCTs). 
Measurement errors in the assessment of behaviour are defined as 
the difference between the reported behaviour and the true behaviour 
which is usually unknown. These measurement errors consist of two 
components, a random and a systematic error component (Cramer et al., 
1993). The random component arises by factors of randomness during 
the collection of behavioural data. Examples are unclear questions or 
distortions in attention and/or motivation on the part of the participant. 
. In the present study, we are interested in systematic errors that arise 
when specific symptoms, such as cognitive impairment or lack of disease 
insight which are well-known phenomena in participants diagnosed 
with Alzheimer’s disease (AD), schizophrenia (SZ) or depression 
(Amador et al., 1993; Reddy, 2016), and cognitive impairment (Millan 
et al., 2012), and can affect the assessment of their own behaviour 
(Doyle et al., 1999; Hayhurst et al., 2014; Pennington et al., 2019; 
Petersen et al., 2019). 
Here, we first compared ratings of social behaviour among neuro-
psychiatric patients diagnosed with schizophrenia (SZ) or probable 
Alzheimer’s Disease (AD) as provided by three sources: (1) self-report, 
(2) study researchers, and (3) caregivers. Given the lack of disease 
insight and cognitive impairments in these psychiatric populations, we 
expected that patients would overestimate their social functioning 
relative to the assessment of others (e.g., caregivers). Subsequently, we 
assessed to what extent the discrepancy between the different assessors 
is mediated by patient symptom severity. Based on previous observa-
tions (Reddy, 2016; Siu et al., 2015), we expected that increases in 
disease severity would be associated with increased overestimation of 
function on the part of the patient relative to informants. Finally, we 
examined if the patient, researcher- or caregiver-rated assessment 
correlated more strongly with an objective indicator of social behaviour 
that was derived from real-world passive remote monitoring of smart-
phone communication behaviour of the patient. 
2. Methods 
2.1. Sample 
The participants in this study were recruited through several clinical 
sites in Spain and the Netherlands as part of the Psychiatric Ratings 
using Intermediate stratified Markers (Kas et al., 2019) (PRISM) 
consortium. The data analysed here were collected from 53 patients with 
a diagnoses of Alzheimer’s disease (AD) according to the criteria as 
outlined by the National Institute on Aging (NIA) and the Alzheimer’s 
Association (AA) (NIA-AA), and 61 patients meeting DSM-IV (Associa-
tion and others, 2000) criteria for schizophrenia (SZ) as confirmed by 
diagnostic interview (the Mini-International Neuropsychiatric Interview 
(Sheehan et al., 1998) (MINI)). Data in this study was collected with 
ethical approval and written informed consent was provided by all 
subjects. 
Inclusion criteria for participants diagnosed with AD were (1) men 
and women aged between 50 and 80 and, (2) a Mini mental state ex-
amination (Folstein et al., 1983) (MMSE) score between 20 and 26. For 
participants diagnosed with SZ, inclusion criteria were (1) aged between 
18 and 45 years, (2) stable medication dosage at least 8 weeks prior to 
recruitment and, (3) a diagnosis of SZ with a disease duration of no 
longer than 15 years. AD and SZ patients were excluded if they presented 
very severe disease symptoms (e.g. a score of ≥22 on the 7-item PANSS 
positive symptom factor for schizophrenia, a score <20 on the MMSE for 
Alzheimer’s Disease), had a current DSM-IV diagnosis of Major 
Depressive Disorder as assessed by the MINI or scored ≥16 on the 
QIDS-SR16, suffered from drug or alcohol dependence within the three 
years prior to screening or had any contraindications for MRI studies. 
Additional exclusion criteria were (1) comorbid mental disorders that 
required intervention or treatment, (2) neurological diseases affecting 
the central nervous system and, (3) clinically important systematic 
illness that affects the ability to complete the study assessments. AD 
patients with a cerebrovascular accident based on patient history or 
imaging (where available) were excluded from recruitment. For a 
detailed overview of the inclusion and exclusion criteria we refer to the 
manuscript of Bilderdeck (Bilderbeck et al., 2019). 
2.2. Measure of social functioning 
To assess the level of social functioning in AD and SZ patients we 
used a subset of five items (items 1–4 from the getting along domain; 
item 6 from the participation domain)(Saris et al., 2017; van der Wee 
et al., 2019) from the WHO Disability Assessment Schedule 2.0 (Üstün 
et al., 2010). This five-item subset of the WHODAS assessed to what 
extend participants were able to engage in interpersonal relations and 
community related activities. Responses on these five items were on a 
Likert scale and ranged between 1 (no problems) to 5 (extreme or cannot 
do). We summed the responses on these five items to calculate a total 
score; higher scores here represent decreased social functioning. To 
acquire assessments from different parties, we asked caregivers and re-
searchers to assess the patient’s overall social functioning by using this 
five-item version of the WHODAS. For 40 AD and 28 SZ participants we 
collected caregiver-rated WHODAS score and for 42 AD and 54 SZ we 
collected researcher-rated WHODAS scores. To assess to what extend AD 
and SZ participants tended to overestimate their social functioning we 
calculated the discrepancies between self-rated and a combined 
researcher/caregiver-rated WHODAS score. 
2.3. Clinical measures of symptom severity 
To assess the severity of symptoms in AD and SZ participants we 
utilized two different questionnaires. For SZ, we utilized the PANSS to 
assess the severity of negative, positive and general psychopathology 
symptoms. Previous studies indicate that between negative and positive 
symptoms, the former is more strongly associated with decreased social 
functioning in SZ (Carpenter et al., 1988; Galderisi et al., 2018). Hence, 
in our analysis we focused on the severity of negative symptoms and 
their association with the discrepancies between self-rated and 
researcher/caregiver-rated WHODAS subset cores. The sum score on the 
negative symptom domain of the PANSS ranges from 7 to 49 points. 
Higher scores on this domain are indicative of more negative symptoms. 
PANSS data was available for a total of 43 SZ participants. Despite the 
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focus on the severity of negative symptoms in SZ, we will also report the 
statistics for the association between the positive symptoms and general 
psychopathology scores. 
For AD, we used the MMSE (Folstein et al., 1983) to assess the 
severity of cognitive impairment. The MSSE assesses 8 different domains 
of cognitive functioning and is scored on a 0- to 30-point scale. Higher 
scores here are indicative of better cognitive functioning. MMSE data 
was available for a subset of 45 AD participants. 
2.4. Smartphone measure of social functioning 
To assess the degree of social functioning in a more objective manner 
smartphone data was collected from a subset of participants. The 
smartphone data used in this study was collected by the BEHAPP 
smartphone application. BEHAPP is a passive behavioural monitoring 
application for Android that collects data by utilizing the embedded 
sensors in participants’ own smartphones. BEHAPP is used for scientific 
research that aims to provide objective, quantitative and longitudinal 
measures of human (social) behaviour to classify, for example, mental 
health disorders based on digital behavioural profiles, develop digital 
biomarkers to study disease progression and treatment efficacy, and 
identify early indicators of disease that allow prediction of disease onset, 
relapse and remission. 
A subset of 19 AD patients and 16 SZ patients provided written 
consent to install the BEHAPP application on their own smartphone and 
to allow passive monitoring of their activities. Smartphone data 
collected over a consecutive period of 14 days was used to extract the 
total number of communication related events measured (i.e. usage of 
communication apps such as WhatsApp, Telegram or Skype) and was 
used as a more objective measure of social behaviour. 
2.5. Statistical analysis 
The statistical analysis for this study was conducted in a stepwise 
manner and aims to describe the association between self-, researcher 
and caregiver-rated WHODAS subset score and an objective measure of 
social behaviour as collected by BEHAPP. First, a two-way ANOVA was 
used to assess the main effect of the different assessors (patient, 
researcher or caregiver) on the WHODAS scores for AD and SZ. Subse-
quently, a post-hoc test with a Tukey correction (Tukey, 1949) was used 
to evaluate the difference between the assessors within each disease 
label. 
In order to assess to what extent participants tended to overestimate 
or underestimate their social functioning, we calculated the discrepancy 
between self-rated and researcher/caregiver-rated WHODAS scores. 
This discrepancy is calculated by combining the researcher- and 
caregiver-rated WHODAS scores. In this manner we were able to obtain 
a single discrepancy score between the self-rated and proxy-rated 
(researcher- and caregiver-rated) WHODAS scores. This discrepancy 
was calculated in the following manner for participants of whom 





discrepancy =WHOP − WHOs (2)  
Where WHOr denotes the researcher-rated WHODAS score, WHOc the 
caregiver, and WHOs the self-rated. First, we calculated the average 
WHODAS score for the proxy-rated assessments (1) and subsequently 
calculated the discrepancy (2). For participants with either researcher or 
caregiver-rated WHODAS scores, discrepancies were calculated by 
subtracting the self-rated from the researcher or caregiver-rated WHO-
DAS scores. By applying this approach, discrepancy data was available 
for 54 SZ and 42 AD participants. Given the Likert scale nature of this 
measure we used a Mann-Whitney U Test to evaluate if the discrepancies 
are significantly higher than zero. Next, we evaluated if the discrep-
ancies are associated with the severity of symptoms in AD and SZ par-
ticipants. Four generalized linear models (GLMs) with a Poisson 
distribution were utilized to assess the main effect of the discrepancies 
on the severity of symptoms (PANSS negative, positive and general 
psychopathology and MMSE). 
Finally, we studied the association between the self-, researcher- and 
caregiver-rated WHODAS scores and the more objective measure of 
behaviour as generated by BEHAPP. A GLM was utilized to assess to 
what extend lower WHODAS scores are associated with decreased 
number of communication events. A total of two GLMs were fitted with 
the different WHODAS scores (average proxy- and self-rated) as a main 
effect and an interaction with disease label (AD or SZ). 
3. Results 
Demographic and symptomatic information about the two patient 
populations is presented in Table 1. The average age of the AD and SZ 
patients who agreed to passively monitor behaviour by using their own 
smartphone is 67.74 ± 7.62 and 31.59 ± 6.40, respectively, and is non- 
significantly different relative to participants that have not participated 
in BEHAPP. AD patients that did participate in BEHAPP had similar 
MMSE scores (24.30 ± 2.03 vs 23.60 ± 2.12) than those who did not 
participate (t(42) = 1.13, p = 0.26). However, for the SZ patients the 
general psychopathology as measured by the PANSS was significantly 
lower (23.07 ± 4.11 vs 26.89 ± 6.14) in the participants participating in 
BEHAPP compared to those that did not participate (t(38) = − 2.41, p =
0.021). 
3.1. Social functioning 
The results of the group-wise comparison of the WHODAS scores are 
presented in Fig. 1. The one-way ANOVA revealed a significant main 
effect of assessor on the WHODAS scores for AD patients (F(2,132) =
20.72, p < 0.001). Post-hoc analyses using the Tukey post-hoc correc-
tion for significance indicated that AD patients tended to significantly 
overestimate their social functioning relative to the assessment of the 
caregiver (b = 3.27, t(132) = 4.65, p < 0.001) and researcher (b = 4.17, t 
(132) = 6.03, p < 0.001). Relative to the assessment of the caregiver 
(Fig. 1A), AD patients tended to overestimate their social functioning on 
average with 3.26 points (33%). This contrast is slightly higher between 
the self- and researcher-rated WHODAS scores. Relative to the 
researcher-rated scores, AD patients overestimated their social func-
tioning on average with 4.17 points (39%)(self-: 6.66 ± 2.53; Caregiver-: 
9.93 ± 3.58; researcher-rated: 10.83 ± 3.97). 
There was no significant effect of assessor on the WHODAS scores for 
SZ patients (F(2,140) = 1.49, p = 0.227)(Fig. 1B). Relative to the 
caregiver- (b = 0.89, t(140) = 0.79, p = 0.708) and researcher-rated (b 
= 1.59, t(140) = 1.72, p = 0.200) WHODAS scores, SZ patients did not 
report their social function significantly different compared to caregiver 
or researcher(self-: 11.43 ± 5.23; Caregiver-: 12.32 (+7%) ± 4.52; 
researcher-rated: 13.02 (+12%) ± 4.83). 
3.2. Discrepancies in WHODAS scores 
Next, we calculated individual discrepancies between the self-rated 
WHODAS and the caregiver- and researcher-rated WHODAS (see 
methods). Positive scores on this measure indicate that patients rated 
their social function as better compared to ratings provided by their 
informant(s). These discrepancies are depicted in Fig. 2. Mann-Whitney 
U Tests showed that for both AD and SZ patients, the discrepancy in 
WHODAS scores was significantly higher than zero (AD: Mann-Whitney 
U = 686, n = 42, p < 0.001; SZ: Mann-Whitney U = 680.5, n = 54, p <
0.004), such that both AD (3.44 ± 3.30) and SZ (1.18 ± 2.74) patients 
reported their social functioning to be significantly higher than that 
reported by their caregivers and researchers. 
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3.3. Association between symptom severity and WHODAS discrepancies 
Fig. 3 depicts the relation between the severity of symptoms and the 
discrepancies between different WHODAS scores. GLM with a Poisson 
distribution revealed that there was a significant and positive relation-
ship between PANSS negative symptom scores and the size of the 
WHODAS discrepancy in SZ participants (b = 0.034, z = 2.193, p =
0.028, Fig. 3A). 
Analysis of the positive symptoms (b = − 0.026, z = − 1.427, p =
0.154) and general psychopathology (b = − 0.023, z = − 1.921, p =
0.055) revealed that both are non-significantly related with WHODAS 
discrepancy in SZ patients. Similarly, a GLM with a Poisson distribution 
revealed that there was a significant and positive relationship between 
MMSE scores and the size of the WHODAS discrepancy in AD partici-
pants (b = − 0.019, z(31) = − 2.346, p = 0.019, Fig. 3B). 
3.4. Association between BEHAPP and WHODAS 
The association between the number of communication events as 
registered by the BEHAPP application and the self-rated and the proxy- 
rated (based on caregiver- and researcher-rated scores) WHODAS scores 
is depicted in Fig. 4. Noteworthy is the significant difference in 
communication events (t-test; t(19) = 4.51, p < 0.001) between AD (133 
± 125) and SZ (480 ± 275) diagnosed participants. GLM analysis 
revealed a non-significant main effect of the self-rated WHODAS on the 
number of smartphone communication events (b = − 16.85, t(29) =
− 1.471, p = 0.076). In contrast, proxy-rated WHODAS scores were 
significantly and negatively related to the number of communication 
events (i.e., improved ratings of social function were related to more 
communication events)(b = − 29.60, t(26) = − 2.331, p = 0.014). 
4. Discussion 
Here we provide evidence to suggest that, relative to the WHODAS 
subset assessment by caregivers and researchers, subjects diagnosed 
with AD and SZ tend to overestimate their level of engagement in 
interpersonal relations and community related activities. Furthermore, 
our results suggest that this overestimation of social functioning is 
mediated by the severity of patient symptoms, namely, by the severity of 
cognitive impairment in AD, and level of negative symptomology in SZ. 
Together, our findings suggest that the validity of self-rated assessments 
of social functioning in SZ and AD patients are affected by disease- 
Table 1 
Demographic information and symptom severity per disease label. WHODAS for each assessor is also presented.  
Alzheimer’s disease WHODAS   
Age (sd) Sex (f/m) Self Caregiver Researcher MMSE BEHAPP 
68.94 (7.29) 24/29 6.66 (2.53) 10.83 (3.97) 9.93 (3.58) 26.77 (7.26) n = 23  
Schizophrenia WHODAS PANSS  
Age (sd) Sex (f/m) Self Caregiver Researcher NTa PTa GTa BEHAPP 
30.13 (6.55) 20/41 11.43 (5.23) 13.02 (4.83) 12.32 (4.52) 14.12 (5.85) 11.51 (3.46) 25.52 (5.75) n = 22  
a NT: Negative symptoms, PT: Positive symptom, GT: General psychopathology. 
Fig. 1. (A) Self-, caregiver and researcher-rated WHODAS scores for AD patients. (B) Self-, caregiver and researcher-rated WHODAS scores for SZ patients. The 
results suggest that AD patients tended to significantly overestimate their social functioning relative to the assessment of the caregiver (b = 3.27, t(132) = 4.65, p <
0.001, n = 40) and researcher (b = 4.17, t(132) = 6.03, p < 0.001, n = 42). For the SZ patient the data suggest a non-significant difference between the over-
estimation of social functioning (caregiver; b = 0.89, t(140) = 0.79, p = 0.708, n = 28) (researcher; b = 1.59, t(140) = 1.72, p = 0.200, n = 54). 
Fig. 2. Discrepancy in WHODAS scores for AD and the Schizophrenia group. 
Mann-Whitney U Test reveals that both are significantly higher than zero (AD: 
Mann-Whitney U = 686, n = 42, p < 0.001, SZ: Mann-Whitney U = 680.5, n =
54, p = 0.004) which suggest that both AD and SZ participants tended to 
overestimate their social functioning. 
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related biases. 
Comparisons of self-rated versus proxy scorings indicate that the 
assessments from the caregiver and researcher are different from the 
patient self-rated score, and pose the question which of these values 
represent the ground truth? While the patient score is suggesting over-
estimation of their level of social functioning relative to the scores of the 
caregiver and researcher, the self-rated assessment may very well reflect 
the subjective experience of social functioning by the patient. To further 
investigate this difference in scoring, we also assessed social behaviour 
of the patient on the basis of social measures derived from their smart-
phone. For that purpose, we compared the WHODAS assessments (by 
patient, caregiver, and researcher) with an objective measure of social 
behaviour, namely by monitoring smartphone communication activities 
in a subgroup of the patients in this study. Compared to the patient 
scores, this analysis revealed a relatively stronger correlation between 
the proxy-rated WHODAS scores and the more objective measure of 
social functioning collected through passive smartphone monitoring. 
These correlations suggest that the proxy-rated (i.e. caregiver, family, 
practitioner) assessments have a better basis in patients to objectively 
quantify behavioural phenotypes, as compared with self-rated assess-
ments made by patients themselves. These findings provide important 
considerations for clinical studies, such RCTs for negative symptoms in 
which social functioning is assessed in these patient populations. 
The present findings suggest that the overestimation based on the 
WHODAS social functioning scores in patients may be affected by 
disease-related biases. Indeed, correlation analysis revealed that higher 
negative symptom scores on the PANSS are associated with stronger 
deviations in WHODAS scores between SZ patients and their proxy-rated 
scores. Comparable findings were observed for AD patients and their 
cognitive performance on the MMSE; the lower the patient’s MMSE 
score (lower cognitive performance), the stronger the deviations in 
WHODAS scores between AD patients and their proxy-rated scores. In 
light of these findings, our observations are consistent with those from 
previous studies (Doyle et al., 1999; Hayhurst et al., 2014; Pennington 
et al., 2019; Petersen et al., 2019) showing the effects of disease-related 
symptoms on behavioural data collected through self-rated assessment 
methods. 
A variety of disease-related factors should be considered in the 
context of our findings. First, lack of disease insight, unawareness, and 
the denial of symptoms are well-established phenomena in subjects 
diagnosed with AD and SZ (Osatuke et al., 2008). Not only are these 
phenomena highly distressing for caregivers, they are linked to severity 
and cognitive impairments for both disorders. Second, it has been shown 
that the lack of insight in patients is associated with the overestimation 
of social functioning relative to patients with milder symptoms (Siu 
et al., 2015). Comparable results are found for AD. Relative to assess-
ment of caregivers, AD patients tend to overestimate their independent 
functioning in everyday life and this overestimation is partly explained 
by the severity of cognitive impairments and lack of insight (Ready et al., 
2006). Altogether, these results support previous findings which suggest 
that increased lack of insight in SZ and AD patients is related to the 
relative overestimation of one’s own social functioning. These findings 
Fig. 3. (A) Negative symptoms as measured by the PANSS vs the discrepancy in WHODAS scores. Results reveal a significant positive relationship (b = 0.034, z =
2.193, p = 0.028, n = 43) which suggest that the overestimation of social functioning is associated with increased negative symptoms in SZ (B) MSSE vs the 
discrepancy in WHODAS scores. Results reveal a significant negative relationship (b = − 0.019, z = − 2.346, p = 0.019, n = 42) which suggest that increased cognitive 
impairment is associated with overestimation of social function in AD. 
Fig. 4. Comparison of smartphone-based measure of communication and self or proxy rated WHODAS assessments. (A) Self-rated (b = − 16.85, t(29) = − 1.471, p =
0.076, n = 27) and (B) proxy-rated (b = − 29.60, t(26) = − 2.331, p = 0.014, n = 27) WHODAS plotted against the number of communication events as registered by 
the BEHAPP application. 
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are in line with the relative overestimation of social functioning with 
increasing disease severity in the present study, and suggest that quality 
of life and social functioning assessments by SZ and AD patients are 
likely to be affected by their cognitive impairments and negative 
symptoms. 
In summary, here we show that relative to the assessment of care-
giver and researchers participants diagnosed with AD and SZ tend to 
overestimate their social functioning. Furthermore, we showed that this 
overestimation is mediated by the severity of cognitive impairments and 
negative symptoms. Important to note is that social functioning in the 
present study is defined as the ability to engage in interpersonal re-
lations and community related activities as measured by the 5 WHODAS 
(Üstün et al., 2010) items. Further research is needed to evaluate 
whether our results are generalizable to other constructs of social 
functioning. For example, it has been shown that for more subjective 
constructs such as pain (Boldingh et al., 2004; Bruera et al., 2001) and 
psychological wellbeing (Bassett et al., 1990) proxy-based assessments 
are less valid. Increased agreement on proxy-based assessments is 
observed between different assessors if the construct is less dependent 
on the judgement or perception of the patients and more on objective 
behaviours such as the count of specific events (Magaziner, 1997). 
Furthermore, it is important to note that, in the present study, the age of 
inclusion of AD patients reflects better the natural history of the disorder 
than that of SZ patients. Also, the DSM-IV criteria used in the study are 
based on an older version of the current manual. In addition, it is 
important to emphasize the lack of a control group in the present study. 
The reason for this is that validated measures for a fine-grained assess-
ment of schizophrenic and/or Alzheimer’s related symptoms in healthy 
controls is lacking within the PRISM project. With current methods such 
as the PANNS and the MSSE the variability on these scores is limited and 
therefor, a comparison between healthy controls and proxy-based as-
sessments is limited. However, without doubt we recognize the value of 
such a comparison since it informs about to what extend SZ and AZ 
patients differ in the overestimation of their social functioning relative 
to healthy controls. 
Although our results indicate that caregiver- and/or researcher- 
based WHODAS assessments of social functioning are consistent and 
relate to objective smartphone measures, care should be taken in 
assuming that these proxy measures adequately capture the ground 
truth of individuals’ social function. To gain a better understanding of 
the variation in human social behaviour and in underlying biological 
mechanisms, we propose to further investigate the use of objective 
methods to quantify social functioning. Recently, researchers started to 
utilize the smartphone as an objective tool to quantify behaviour, 
including social behaviour. This so-called digital phenotyping utilises 
the wide variety of sensors in a smartphone to passively monitor 
behaviour in a longitudinal manner. Key features of this approach are 
that 1) data is collected in real-time, 2) in the participant’s natural 
environment, and 3) without the need for any self- or proxy reporting, 
thereby addressing some of the most important challenges inherent to 
current behavioural research. Here we showed that the quantification of 
a relatively simple event such as communication events as registered by 
a smartphone may provide potential indicators of social functioning. 
However, further studies are needed to develop and optimize novel 
objective, longitudinal, quantitative and real-world measures of social 
functioning. 
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